# US 2019/0153394 A1 · Generation of pancreatic endoderm from pluripotent stem cells using small molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0153394 A1
- Document ID: US20190153394A1
- Status: Published application
- Kind: A1
- Application number: 16/255,347
- Filed: 2019-01-23
- Published: 2019-05-23
- Earliest claimed: 2012-09-03
- Assignees: Novo Nordisk A/S; Takara Bio Europe AB
- Applicants: Novo Nordisk A/S; Takara Bio Europe AB
- Inventors: Jenny Ekberg; Mattias Hansson; Ulrik Doehn; Katja Hess; Nina Funa
- Web page: https://patentgrep.com/patent/US20190153394A1

## CPC

- C12N 5/0676: {Pancreatic cells}
- C12N 5/0678: {Stem cells; Progenitor cells; Precursor cells}
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/117: Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/60: Transcription factors
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2503/02: Drug screening
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of producing pancreatic cells or pancreatic cell precursors expressing at least 5% PDX1/NKX6.1 double positive, comprising exposing definitive endoderm cells to an effective amount of one or more small molecules, to differentiate the human definitive endoderm cells into the pancreatic cells or pancreatic cell precursors. The present invention also relates to pancreatic endoderm cells produced by said methods and uses of said pancreatic endoderm cells.

## Claims

### Claim 1

A cell culture medium comprising definitive endoderm cells, a BMP inhibitor, JNK inhibitor II, bFGF, and a retinoic acid receptor agonist.

### Claim 2 (depends on 1)

The cell culture medium of claim 1, wherein the BMP inhibitor is

### Claim 3 (depends on 1)

The cell culture medium of claim 1, wherein the retinoic acid receptor agonist is

### Claim 4 (depends on 1)

The cell culture medium of claim 1, wherein the BMP inhibitor is
and the retinoic acid receptor agonist is
